ClinicalTrials.gg
RecruitingNCT05228431Updated Apr 22, 2024

Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

A Phase 2 interventional study of XELOX and Capecitabine monotherapy in Advanced Rectal Cancer, sponsored by Zhen-Hai Lu. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Zhen-Hai Lu · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing xelox in Rectal Neoplasms — 6 open to participants now, 8 under way, 1 of them phase 3. xelox · Rectal Neoplasms.

Planned enrollment
6th of 16
121 · median 82
Started
2022
with 2 others
Phase 2
13 of 16
4 open now
Registered
11th of 16
by date

Among the 16 studies testing xelox in Rectal Neoplasms, this one is the 6th largest by planned enrollment, is one of 3 that started in 2022, is one of 13 in phase 2, and was the 11th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

6 of the 16 studies testing xelox in Rectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About xelox

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing xelox in Rectal Neoplasms, or all of them as a file.
02

Study summary

In the treatment of locally advanced rectal cancer, the short-term and long-term efficacy of the traditional sandwich regimen has not reached satisfactory efficacy. For this reason, the concept of reducing the dose of postoperative chemotherapy or directly moving forward the full amount of postoperative chemotherapy was proposed, which is called total neoadjuvant therapy (TNT). However, TNT also includes the high toxicity of oxaliplatin in the whole process and the long time interval between the end of radiotherapy and the operation, which leads to fibrosis of the surrounding tissue, which increases the difficulty of surgical resection and makes it difficult to ensure good surgical specimen quality. In addition to this, there are issues that may increase the risk of potential disease progression in patients with poor treatment withdrawal. Therefore, appropriately reducing the intensity of chemotherapy and controlling the total duration of preoperative neoadjuvant therapy during radiotherapy is expected to alleviate the side effects of neoadjuvant therapy. Here, the investigators synthesized the characteristics of TNT and sandwich regimens and proposed a XELOX regimen and capecitabine alternate administration combined with preoperative intensity modulated radiation therapy.

03

Conditions studied

  • Advanced Rectal Cancer

Browse trials for

Keywords

  • Rectal cancer
  • neoadjuvant chemoradiotherapy
  • optimization
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pathological confirmed rectal adenocarcinoma.

Clinical stage T3-4 or T any N1.With or without MRF positivity, with or without EMVI positivity, R0 resection is estimated.

No

No signs of intestinal obstruction; or intestinal obstruction has been relieved after proximal colostomy surgery.

Age ranged from 18 to 75

No previous radiotherapy,surgery and chemotherapy.

Exclusion criteria

Exclusion Criteria:

Multiple primary tumor

Cachexy

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
121 participants (estimated)

Study arms

  • Experimental
    Sandwich Regimen

    All rectal patients in this group will receive standard surgical resection.

    Drug: XELOX · Drug: Capecitabine monotherapy · Radiation: Radiation

Interventions

  • DrugXELOX

    Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.

  • DrugCapecitabine monotherapy

    During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.

  • RadiationRadiation

    The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.

06

What researchers measure

Primary outcomes

  1. Rate of pCR

    rate of pathological complete remission

    Time frame: One week after surgery

Secondary outcomes

  1. DFS

    Disease free survival

    Time frame: 3 years

  2. OS

    overall survival

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Zhenhai Lu
    Guangzhou, Guangdong, China
    Recruiting
    • Zhenhai Lu, Prof · Contactluzhh@sysucc.org.cn · +86 20 87343584
    • Jianhong Peng, Doctor · Contactpengjh@sysucc.org.cn · +86 20 87343584
    • Zhifan Zeng, M.D · Sub investigator
    • Xiaojun Wu, M.D · Sub investigator
    • Junzhong Lin, M.D · Sub investigator
    • Rongxin Zhang, M.D · Sub investigator
    • Weiwei Xiao, M.D · Sub investigator
    • Yujing Fang, Ph.D · Sub investigator
    • Fulong Wang, M.D · Sub investigator
    • Jianhong Peng, M.D · Sub investigator
    • Yuan Li, M.D · Sub investigator
    • Qingjian Ou, M.D · Sub investigator
    • Weili Zhang, M.D · Sub investigator
    • Jiali Chen, M.D · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for May 2027, 61 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 61 months is above that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2022
First posted
Feb 8, 2022
StartActual
Mar 2, 2022
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2028
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05228431
Lead sponsor
Zhen-Hai Lu
Responsible party
Zhen-Hai Lu (Pofessor, Sun Yat-sen University) — Sponsor-investigator
First posted
Feb 8, 2022
Start date
Mar 2, 2022
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Apr 22, 2024

Study contacts

Zhenhai Lu, Prof
Contact
luzhh@sysucc.org.cn
+862087343584
Jianhong Peng, M.D
Contact
pengjh@sysucc.org.cn
+862087343584

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xelox

Start the discussion